ArticleJAMA2019
Association of HIV Preexposure Prophylaxis With Incidence of Sexually Transmitted Infections Among Individuals at High Risk of HIV Infection.
Article in JAMA, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06860945 (Development of a Predictive Model for Sexually Transmitted Infections in Individuals Using Pre-Exposure Prophylaxis for HIV in Spain), which is not on this map. Cited by 187 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Development of a Predictive Model for Sexually Transmitted Infections in Individuals Using Pre-Exposure Prophylaxis for HIV in Spain
Who cites it
187 citing papers in PubMed, 5 syntheses or guidelines pooled it, 392 citations in OpenAlex.
- Male Circumcision and HIV Risk Compensation Among Men Who Have Sex with Men: A Systematic Review and Meta-Analysis.AIDS and behavior · 2026Pooled it
- CDC Clinical Guidelines on the Use of Doxycycline Postexposure Prophylaxis for Bacterial Sexually Transmitted Infection Prevention, United States, 2024.MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports · 2024Guideline
- Impact of daily, oral pre-exposure prophylaxis on the risk of bacterial sexually transmitted infections among cisgender women: a systematic review and narrative synthesis.Wellcome open research · 2022Pooled it
- Sexual discounting: A systematic review of discounting processes and sexual behavior.Experimental and clinical psychopharmacology · 2021Pooled it
- Global Burden and Changing Trend of Hepatitis C Virus Infection in HIV-Positive and HIV-Negative MSM: A Systematic Review and Meta-Analysis.Frontiers in medicine · 2021Pooled it
- Doxycycline Prophylaxis to Prevent Sexually Transmitted Infections in Women.The New England journal of medicine · 2023Trial
- "The Main Concern is HIV, Everything Else is Fixable": Indifference Toward Sexually Transmitted Infections in the Era of Biomedical HIV Prevention.AIDS and behavior · 2021Trial
- Resistance-Guided Treatment of Gonorrhea: A Prospective Clinical Study.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2021Trial
- Trial
- Trial
- Perspectives on Analytical Treatment Interruptions and Prospects of an HIV Cure Amongst People Living with HIV and Healthcare Providers in Singapore.AIDS and behavior · 2026Article
- Pre-exposure prophylaxis adherence and risks of HIV and sexually transmitted infection among adult men before vs during the COVID-19 pandemic.Journal of managed care & specialty pharmacy · 2026Article
- Trends in Pre-exposure Prophylaxis Use, Condom Use, and Sexually Transmitted Infections Among Men Who Have Sex with Men from 2014, 2017, and 2023.AIDS and behavior · 2026Article
- Awareness, attitudes and early use of doxycycline prophylaxis among gbMSM in Ireland: findings from a 2025 community-based cross-sectional survey.Sexually transmitted infections · 2026Article
- HIV Preventive Measures' Adoption Among Men Who Have Sex With Men in West and Central Africa: A Scoping Review On Pre-exposure Prophylaxis and Condom Use.Journal of community health · 2026Review
- Innovations and Challenges in Syphilis Screening and Prevention Among Men Who Have Sex With Men: A Scoping Review.Sexually transmitted diseases · 2026Article
- Vaccination Coverage and Prevention Counselling for Vaccine-Preventable STIs Among HIV PrEP Users in São Paulo, Brazil: A Retrospective Cohort Study.Journal of the International AIDS Society · 2026Article
- Penile human papilloma virus (HPV) in high risk populations with and without HIV: Epidemiological insights from Argentina.International journal of STD & AIDS · 2026Article
- Structural and Social Drivers of Pre-Exposure Prophylaxis (PrEP) Literacy Disparities Among Men who have Sex with Men in China: A PrEP Care Cascade Analysis.AIDS and behavior · 2026Article
- Pre-exposure Prophylaxis Outcomes in High-Risk Individuals in Saudi Arabia: A 48-Week Observational Cohort Study.Cureus · 2026Article
127 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
32 authors at 8 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Importance: Emerging evidence suggests that risk of bacterial sexually transmitted infections (STIs) increases among gay and bisexual men following initiation of HIV preexposure prophylaxis (PrEP). Objective: To describe STI incidence and behavioral risk factors among a cohort of predominantly gay and bisexual men who use PrEP, and to explore changes in STI incidence following PrEP commencement. Design, Setting, and Participants: The Pre-exposure Prophylaxis Expanded (PrEPX) Study, a multisite, open-label intervention study, was nested within the Australian Collaboration for Coordinated Enhanced Sentinel Surveillance (ACCESS) clinic network. A total of 4275 participants were enrolled (July 26, 2016-April 1, 2018) in Victoria, Australia. Of these, 2981 enrolled at 5 ACCESS clinics (3 primary care, 1 sexual health, and 1 community-based HIV rapid testing service), had at least 1 follow-up visit, and were monitored until April 30, 2018. Exposures: Upon enrollment, participants received daily oral tenofovir disoproxil fumurate and emtricitabine for HIV PrEP, quarterly HIV and STI testing, and clinical monitoring. Main Outcomes and Measures: The primary outcome was incidence of chlamydia, gonorrhea, or syphilis. Incidence rates and hazard ratios describing behavioral risk factors of STI diagnosis were calculated. Incidence rate ratios (IRRs), adjusted for change in testing frequency, described changes in STI incidence from 1-year preenrollment to study follow-up among participants with preenrollment testing data (n = 1378). Results: Among the 2981 individuals (median age, 34 years [interquartile range, 28-42]), 98.5% identified as gay or bisexual males, 29% used PrEP prior to enrollment, 89 (3%) withdrew and were censored at date of withdrawal, leaving 2892 (97.0%) enrolled at final follow-up. During a mean follow-up of 1.1 years (3185.0 person-years), 2928 STIs were diagnosed among 1427 (48%) participants (1434 chlamydia, 1242 gonorrhea, 252 syphilis). STI incidence was 91.9 per 100 person-years, with 736 participants (25%) accounting for 2237 (76%) of all STIs. Among 2058 participants with complete data for multivariable analysis, younger age, greater partner number, and group sex were associated with greater STI risk, but condom use was not. Among 1378 participants with preenrollment testing data, STI incidence increased from 69.5 per 100 person-years prior to enrollment to 98.4 per 100 person-years during follow-up (IRR, 1.41 [95% CI, 1.29-1.56]). After adjusting for testing frequency, the increase in incidence from 1 year preenrollment to follow-up was significant for any STI (adjusted IRR, 1.12 [95% CI, 1.02-1.23]) and for chlamydia (adjusted IRR, 1.17 [95% CI, 1.04-1.33]). Conclusions and Relevance: Among gay and bisexual men using PrEP, STIs were highly concentrated among a subset, and receipt of PrEP after study enrollment was associated with an increased incidence of STIs compared with preenrollment. These findings highlight the importance of frequent STI testing among gay and bisexual men using PrEP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.